Skip to main content
AI Market Summary
Loading market intelligence...

Aimmune Therapeutics, Inc. (AIMT) Stock Forecast 2025 - AI Price Prediction & Analysis


Aimmune Therapeutics, Inc. (AIMT) AI Stock Price Forecast & Investment Analysis

Aimmune Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading Aimmune Therapeutics, Inc. interactive price chart and technical analysis...

Aimmune Therapeutics, Inc. (AIMT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Aimmune Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Aimmune Therapeutics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Aimmune Therapeutics, Inc.: Aimmune Therapeutics, Inc. operates in the Health Technology sector, establishing it as a mid-cap growth opportunity.

Aimmune Therapeutics, Inc. (Stock Symbol: AIMT) is a leading company in the Health Technology sector , specifically operating within the Biotechnology industry.

The organization employs approximately 275 professionals worldwide and operates under the strategic leadership of CEO Jayson Donald Alexander Dallas.

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Aimmune Therapeutics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Aimmune Therapeutics, Inc.: With $1M in annual revenue, the company demonstrates developing profitability.

Annual Revenue: $1 million .

Market Capitalization: $2207 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -149.2% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Aimmune Therapeutics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Aimmune Therapeutics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Aimmune Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Aimmune Therapeutics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Aimmune Therapeutics, Inc.: Market positioning analysis based on available financial and operational metrics.

Aimmune Therapeutics, Inc. strategically competes in the highly dynamic Biotechnology marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

Aimmune Therapeutics, Inc. (AIMT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Aimmune Therapeutics, Inc. stock analysis.

Loading Aimmune Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Aimmune Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Aimmune Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Aimmune Therapeutics, Inc.: With a P/E ratio of -7.68, the market sees the stock as potentially undervalued.

P/E Ratio -7.68x
P/B Ratio 12.54x
Market Cap $2207M
EPS $-4.49
Book Value/Share $2.75
Revenue/Share $0.02
FCF/Share $-3.28
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Aimmune Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Aimmune Therapeutics, Inc.: An ROE of -149.2% indicates room for improvement in shareholder value creation.

ROE -149.2%
ROA -86.5%
ROIC -98.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Aimmune Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Aimmune Therapeutics, Inc.: A current ratio of 7.53 indicates strong liquidity.

Current Ratio 7.53x
Quick Ratio 7.30x
D/E Ratio 0.78x
Financial Leverage 2.03x
Interest Coverage -35.0x
Working Capital $102M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Aimmune Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Aimmune Therapeutics, Inc.: Free cash flow of $-234M indicates cash challenges that need attention.

Operating Cash Flow $-230M
Free Cash Flow $-234M
Capital Spending $-4M
CapEx/Sales 694.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Aimmune Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Aimmune Therapeutics, Inc.:

Receivables Turnover 23.0x
Fixed Assets Turnover 0.0x
Days Sales Outstanding 16 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Aimmune Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Aimmune Therapeutics, Inc.: With annual revenue of $1M, Aimmune Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $1M
Operating Income $-283M
Net Income $-287M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 89%
Cash & Short-term Investments 86%
Total Liabilities 51%
Accounts Receivable 0%
Inventory 2%
Dividend & Shareholder Information
Shares Outstanding 64M

Latest Aimmune Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Aimmune Therapeutics, Inc. (AIMT) stock price and investment outlook.

, source: BioWorld

Less than a month after would-be competitor DBV Technologies SA suffered a regulatory setback with its peanut allergy patch candidate, Aimmune Therapeutics Inc. – which at the start of the year gained ...

, source: Insider Monkey

Coronavirus is probably the #1 concern in investors’ minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We ...

, source: MarketWatch

Nestle SA said Monday that it has entered into a definitive agreement for the acquisition of U.S.-based biopharmaceutical company Aimmune Therapeutics Inc. by its subsidiary Nestle Health Science, or ...

, source: Benzinga.com

Société des Produits Nestlé S.A. (“Nestlé”) announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. (“Purchaser”), is commencing today a cash tender offer to purchase all of the outstanding ...

Aimmune Therapeutics, Inc. Competitors & Peer Analysis - Health Technology Sector

Comparative analysis of Aimmune Therapeutics, Inc. against industry peers and competitors in the Health Technology sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Aimmune Therapeutics, Inc. Stock Forecast

How accurate are Aimmune Therapeutics, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for AIMT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Aimmune Therapeutics, Inc. stock price forecasts?

Our analysis considers Aimmune Therapeutics, Inc.'s financial metrics, Health Technology sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Aimmune Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Aimmune Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Aimmune Therapeutics, Inc. forecasts updated?

Aimmune Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Aimmune Therapeutics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Aimmune Therapeutics, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...